LivaNova Q1 revenue $294.9M (+12% YoY); raises FY2024 guidance; OSPREY study positive

LivaNova PLC

2024-Q1 EPS reported -$0.78 revenue$294,912,000

Q1 revenue $294.9M, up 12.0% reported, 12.4% constant-currency YoY; adjusted EPS $0.73 vs GAAP loss $0.78.
Cardiopulmonary and Neuromodulation each grew double-digit; ACS wind down on track for end-2024.
Raised full-year 2024 revenue and adjusted diluted EPS guidance (exact figures not in excerpt).
Positive predictive outcome in OSPREY obstructive sleep apnea study; enrollment completed.
Closed $345M 2.50% convertible notes due 2029; repurchased $230M exchangeable notes due 2025.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

LivaNova PLC reported quarter ended March 31, 2024 results: revenue $294.9 million. Guidance raised.

Period: quarter ended March 31, 2024
Revenue: $294.9 million
Guidance: raised
Result: reported results

Exact text from the filing

quarter ended March 31, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance. Financial Summary and Highlights (1) • First-quarter revenue of $294.9 million increased 12.0% on a reported basis and 12.4% on a constant-currency basis, as compared to the prior-year period. Excluding the impact of the Advanced Circulatory Support (ACS)

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

LivaNova PLC reported first quarter 2024 results: EPS First-quarter U.S. GAAP diluted loss per share was $0.78 and adjusted diluted earnings per share was $0.73.

Period: first quarter 2024
EPS: First-quarter U.S. GAAP diluted loss per share was $0.78 and adjusted diluted earnings per share was $0.73
Result: reported results

Exact text from the filing

First-quarter U.S. GAAP diluted loss per share was $0.78 and adjusted diluted earnings per share was $0.73

View on SEC.gov

710 earnings releases filed in the last 30 days. Browse all earnings releases →

LivaNova PLC filing history →

Source: SEC EDGAR

accession 0001639691-24-000054

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.